The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001:433–517., . The biogenesis of membranes and organelles. In: , , .
The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151–6., , .
Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annu Rev Genomics Hum Genet 2003;4:403–36., .
Blood to brain to the rescue. J Clin Invest 2004;113:1108–10., .
The cell biology of glycosphingolipids. Semin Cell Dev Biol 2004;15:375–87., , .
The metabolic and molecular bases of inherited disease. New York: McGraw Hill, 2001:3635–68., . Gaucher disease. In: , , .
Prevalence of lysosomal storage disorders. JAMA 1999;281:249–54., , , .
The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2006: in press., , . Gaucher disease: phenotypic and genetic variation. In: , , , .
Hepatic response to enzyme replacement therapy (ERT) with mannose-terminated glucocerebrosidase in type 1 Gaucher disease. Hepatology 2004;40:161., , .
Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. Q J Med 2000;93:237–44., , .
Liver abnormalities in patients with Gaucher's disease. Gastroenterology 1981;80:126–33., , , .
Gaucher disease: hepatic abnormalities in 25 patients. Prog Clin Biol Res 1982;95:131–42., , , .
Gaucher's disease and fatal hepatic fibrosis despite prolonged enzyme replacement therapy. Pediatrics 2002;109:1170–3., , .
Hepatocellular carcinoma in a patient with Gaucher disease on enzyme supplementation therapy. Ann Oncol 1999;10:243., , .
Replacement therapy for inherited enzyme deficiency – macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464–70., , .
Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004;41:15–22., , .
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112–19., , .
Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J 1996;13:153–7..
Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis 2001;24:275–90., , .
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481–5., , .
The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr 2001;138:539–47., , .
Gaucher disease: enzyme therapy in the acute neuronopathic variant. Am J Med Genet 1997;71:16–21., , , .
Screening of 25 Italian patients with Niemann-Pick A reveals fourteen new mutations, one common and thirteen private, in SMPD1. Hum Mutat 2004;24:105., , .
Acid sphingomyelinase: identification of nine novel mutations among Italian Niemann Pick type B patients and characterization of in vivo functional in-frame start codon. Hum Mutat 2004;24:186–7., , .
Seven novel acid sphingomyelinase gene mutations in Niemann-Pick type A and B patients. Ann Hum Genet 2003;67:63–70., , .
The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001:3589–610., . Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies. In: , , .
The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am J Hum Genet 2002;71:1413–19., , .
Acid sphingomyelinase deficiency. Phenotype variability with prevalence of intermediate phenotype in a series of twenty-five Czech and Slovak patients. A multi-approach study. J Inherit Metab Dis 2005;28:203–27., , .
The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study. Pediatrics 2004;114:e672–7., , .
Fatal liver failure in two children with Niemann-Pick disease type B. J Pediatr Gastroenterol Nutr 1991;13:104–9., , .
Chronic Niemann-Pick disease with sphingomyelinase deficiency in two brothers with mental retardation. Eur J Pediatr 1978;128:235–40., , .
Heterogeneity of liver disorder in type B Niemann-Pick disease. Hum Pathol 1997;28:385–8., , .
Cirrhosis and portal hypertension in a patient with adult Niemann-Pick disease. Gastroenterology 1991;100:567–9., , .
Hepatic failure in adult Niemann-Pick disease. Am J Med Sci 1986;292:168–72., .
Long-term survival after liver transplantation in children with metabolic disorders. Pediatr Transplant 2002;6:295–300., , .
Orthotopic liver transplantation in two adults with Niemann-Pick and Gaucher's diseases: implications for the treatment of inherited metabolic disease. Hepatology 1993;17:42–9., , .
Niemann-Pick disease: sixteen-year follow-up of allogeneic bone marrow transplantation in a type B variant. J Inherit Metab Dis 2003;26:775–85., , .
Allogeneic bone marrow transplantation for Niemann-Pick disease (type IA). Bone Marrow Transplant 1992;10(suppl 1):85–6., , .
Molecular analysis of acid ceramidase deficiency in patients with Farber disease. Hum Mutat 2001;17:199–209., , .
The metabolic and molecular bases of inherited disease. New York: McGraw Hill, 2001:3573–88., , . Acid ceramidase deficiency: Farber lipogranulomatosis. In: , , .
Farber's disease. Report of a case with observations on its histogenesis and notes on the nature of the stored material. J Pediatr 1962;61:221–32., , , .
Farber disease: an ultrastructural study. Report of a case and review of the literature. Virchows Arch A Pathol Anat Histopathol 1992;420:281–90., , , .
Farber disease with prolonged survival. J Inherit Metab Dis 1993;16:915–16., , , .
Phenotypic variability in siblings with Farber disease. J Pediatr 1984;104:406–9., , .
Clinical diagnosis of a new case of ceramidase deficiency (Farber's disease). J Inherit Metab Dis 1985;8:8., , .
Bone marrow involvement and obstructive jaundice in Farber lipogranulomatosis: clinical and autopsy report of a new case. J Inherit Metab Dis 1996;19:655–60., , .
Hydrops fetalis: manifestation in lysosomal storage diseases including Farber disease. Eur J Pediatr 1997;156:292–5., , .
Intrauterine fetal death due to Farber disease: case report. Pediatr Dev Pathol 2000;3:597–602., , .
Bone marrow transplantation for infantile ceramidase deficiency (Farber disease). Bone Marrow Transplant 2000;26:357–63., , .
Successful hematopoietic stem cell transplantation in Farber disease. J Pediatr 2004;144:132–4., , .
Four novel mutations in patients from the Middle East with the infantile form of GM1-gangliosidosis. Hum Mutat 2004;24:352., , .
β-Galactosidase gene mutations affecting the lysosomal enzyme and the elastin-binding protein in GM1-gangliosidosis patients with cardiac involvement. Hum Mutat 2000;15:354–66., , .
GM1 gangliosidosis in adults: clinical and molecular analysis of 16 Japanese patients. Ann Neurol 1992;31:328–32., , .
GM1 gangliosidosis presenting as neonatal ascites. J Pediatr 1982;100:940–3., , .
Infantile G(M1) gangliosidosis: complete morphology and histochemistry of two autopsy cases, with particular reference to delayed central nervous system myelination. Pediatr Dev Pathol 2000;3:73–86., , , .
Lysosomal storage diseases presenting as transient or persistent hydrops fetalis. Genet Couns 1991;2:227–32., , .
β-Galactosidase deficiency in juvenile and adult patients. Report of six Japanese cases and review of literature. Hum Genet 1977;36:219–29., , .
Pathologic quiz case: hepatosplenomegaly in an infant with hypotonia and coarse facial features. Gangliosidosis type 1. Arch Pathol Lab Med 2004;128:1297–8., , , .
The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001:3775–809., , . β-Galactosidase deficiency (β-galactosidosis): GM1 gangliosidosis and morquio B disease. In: , , .
Type 2 GM1 gangliosidosis with long survival and neuronal ceroid lipofuscinosis. Neurology 1981;31:719–24., , .
The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001:3611–33., , . Niemann-Pick Disease Type C: A Lipid Trafficking Disorder. In: , , .
Niemann-Pick C1 disease: correlations between NPC1 mutations, levels of NPC1 protein, and phenotypes emphasize the functional significance of the putative sterol-sensing domain and of the cysteine-rich luminal loop. Am J Hum Genet 2001;68:1373–85., , .
Niemann-Pick disease type C. Clin Genet 2003;64:269–81., .
Identification of HE1 as the second gene of Niemann-Pick C disease. Science 2000;290:2298–301., , .
The integrity of a cholesterol-binding pocket in Niemann-Pick C2 protein is necessary to control lysosome cholesterol levels. Proc Natl Acad Sci U S A 2003;100:2518–25., , , .
Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification. A collaborative study on 70 patients. Clin Genet 1988;33:331–48., , .
Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. J Pediatr 1993;123:242–7., , .
Liver disease in infancy: a 20 year perspective. Gut 1991;(suppl):S123–8., , .
Niemann-pick disease type C in neonatal cholestasis at a North American Center. J Pediatr Gastroenterol Nutr 2002;35:44–50., , .
Clinical spectrum of Niemann-Pick disease type C. Neurology 1989;39:1040–9., , .
Niemann-Pick disease type C: an update. J Inherit Metab Dis 1991;14:580–95., , , .
An adult with a non-neuronopathic form of Niemann-Pick C disease. J Inherit Metab Dis 1999;22:84–6., , .
Niemann-Pick disease type C in adults. J Inherit Metab Dis 2002;25:491–500., , .
Fetal Niemann-Pick disease type C: ultrastructural and lipid findings in liver and spleen. Virchows Arch A Pathol Anat Histopathol 1993;422:253–9., , .
Niemann-Pick disease type C. Pathological, histochemical, ultrastructural and biochemical studies. Eur J Pediatr 1981;136:263–74., , , .
Niemann-Pick disease and giant cell transformation of the liver. Acta Paediatr Scand 1971;60:285–94., , .
Pulmonary infiltration in Niemann-Pick disease type C. J Inherit Metab Dis 1996;19:792–3., , , .
Metastatic hepatocellular carcinoma in a patient with niemann-pick disease, type C. J Pediatr Gastroenterol Nutr 2003;37:624–6., , .
Early-lethal pulmonary form of Niemann-Pick type C disease belonging to a second, rare genetic complementation group. Eur J Pediatr 1998;157:45–9., , .
The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease type C. Neurology 1993;43:61–4., , .
Niemann-Pick disease type C (a cellular cholesterol lipidosis) treated by bone marrow transplantation. Bone Marrow Transplant 1999;24:103–7., , .
Progression of neurovisceral storage disease with supranuclear ophthalmoplegia following orthotopic liver transplantation. Pediatrics 1986;77:104–6., , .
The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001;3507–33.. Disorders of glycoprotein degradation: α-mannosidosis, β-mannosidosis, fucosidosis, and sialidosis. In: , , .
Fucosidosis revisited: a review of 77 patients. Am J Med Genet 1991;38:111–31., , .
Spectrum of mutations in fucosidosis. Eur J Hum Genet 1999;7:60–7., , .
Hepatic ultrastructure in mucolipidosis I (lipomucopolysaccharidosis). Virchows Arch B Cell Pathol 1971;7:189–204., , .
Allogeneic bone marrow transplantation for fucosidosis. Bone Marrow Transplant 1995;15:153–8., , .
Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation. Bone Marrow Transplant 2001;27:747–51., , .
Spectrum of mutations in α-mannosidosis. Am J Hum Genet 1999;64:77–88., , .
Mannosidosis: clinical, morphologic, immunologic, and biochemical studies. Pediatr Res 1976;10:985–96., , .
Neurological impairment in α-mannosidosis: a longitudinal clinical and MRI study of a brother and sister. Childs Nerv Syst 1999;15:369–71., , .
Histomorphologic and histochemical investigations in mannosidosis. A light and electron microscopic study. Virchows Arch B Cell Pathol 1977;26:159–73., , .
Bone marrow transplantation for the treatment of α-mannosidosis. J Pediatr 1998;133:282–5., , .
T-cell-depleted peripheral blood stem cell transplantation for α-mannosidosis. Bone Marrow Transplant 2003;32:443–6., , .
Sialidosis: a review of human neuraminidase deficiency. Am J Hum Genet 1979;31:1–18., .
Neuraminidase deficiency: case report and review of the phenotype. J Med Genet 1987;24:283–90., , .
The metabolic and molecular bases of inherited disease. New York: McGraw Hill, 2001:3811–26., , , . Galactosialidosis. In: , , .
Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A. EMBO J 1998;17:1588–97., , .
A severe infantile sialidosis: clinical, biochemical, and microscopic features. J Pediatr 1980;96:662–8., , .
Early-infantile galactosialidosis with multiple brain infarctions: morphological, neuropathological and neurochemical findings. Acta Neuropathol (Berl) 1997;93:24–33., , , .
Early-infantile galactosialidosis: prenatal presentation and postnatal follow-up. Am J Med Genet 1999;85:38–47., , .
A peptidase in human platelets that deamidates tachykinins. Probable identity with the lysosomal “protective protein.” J Biol Chem 1990;265:11265–72., , .
Inactivation of endothelin I by deamidase (lysosomal protective protein). J Biol Chem 1992;267:2872–5., , .
Cathepsin A deficiency in galactosialidosis: studies of patients and carriers in 16 families. Pediatr Res 1996;39:1067–71., , .
Human lysosomal protective protein has cathepsin A-like activity distinct from its protective function. J Biol Chem 1991;266:14754–62., , .
The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001;3389–420., . Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. In: , , .
Acid α-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2002;2:145–66., , .
The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332–40., , .
Pompe disease in infants and children. J Pediatr 2004;144:S35–43., .
Pompe's disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle. Acta Neuropathol (Berl) 1973;23:229–44., , , .
Identification of two subtypes of infantile acid maltase deficiency. J Pediatr 2000;137:283–5., , .
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005;128:671–7., , .
Elevation of transaminases as an early sign of late-onset glycogenosis type II. Eur J Pediatr 1993;152:784., , .
A biochemical and ultrastructural study of liver, muscle, heart and kidney in type II glycogenosis. Virchows Arch B Cell Pathol 1970;4:196–207., .
Bone marrow transplantation for glycogen storage disease type II (Pompe's disease). N Engl J Med 1986;314:385., , , .
Safety and efficacy of recombinant acid α-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005;15:24–31., , .
Enzyme replacement therapy in classical infantile Pompe disease: results of a ten-month follow-up study. Neuropediatrics 2005;36:6–11., , , .
Recombinant human α-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356:397–8., , .
Enzyme therapy for Pompe disease with recombinant human α-glucosidase from rabbit milk. J Inherit Metab Dis 2001;24:266–74., , .
Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 2004;55:495–502., , .
Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3:132–8., , .
New lysosomal acid lipase gene mutants explain the phenotype of Wolman disease and cholesteryl ester storage disease. J Lipid Res 1998;39:1382–8., , .
The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001:3551–72., . Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. In: , , .
Pediatric gastrointestinal disease: pathophysiology, diagnosis and management. Hamilton, Ontario: BC Decker, 2004:1429–39., , . Lysosomal acid lipase deficiencies: Wolman disease and cholesteryl ester storage disease. In: , , .
Wolman disease and cholesteryl ester storage disease diagnosed by histological and ultrastructural examination of intestinal and liver biopsy. Pathol Res Pract 2004;200:231–40., , .
Severe chronic diarrhea and weight loss in cholesteryl ester storage disease: a case report. World J Gastroenterol 2005;11:2364–6., , .
Wolman's disease. An electron microscopic, histochemical, and biochemical study. Arch Pathol 1970;89:103–10., , .
Wolman's disease: a clinicopathologic, electron microscopic, and histochemical study. South Med J 1982;75:595–6., , .
Wolman's disease in an infant. Br J Haematol 2003;122:522., , , .
Wolman's disease. Eur Neurol 1968;1:334–62., , .
Wolman's disease. A rare lipidosis with adrenal calcification. Arch Dis Child 1969;44:331–41., , , .
Case 4. Wolman's disease. Pediatr Pathol 1989;9:193–8., .
A case of Wolman's disease. Helv Paediatr Acta 1971;26:98–111., , , .
Cholesterol ester storage disease: clinical, biochemical, and pathological studies. J Pediatr 1977;90:910–14., , , .
Molecular defects underlying Wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease. J Lipid Res 1999;40:221–8., , .
Regulation of plasma cholesterol by lipoprotein receptors. Science 1981;212:628–35., , .
Wolman's disease: a review of treatment with bone marrow transplantation and considerations for the future. Bone Marrow Transplant 1992;10(suppl 1):97–101., , , .
Wolman disease successfully treated by bone marrow transplantation. Bone Marrow Transplant 2000;26:567–70., , .
Orthotopic liver transplantation for cholesteryl ester storage disease. J Clin Gastroenterol 1991;13:482–5., , .
Cholesteryl ester storage disease: hepatopathology and effects of therapy with lovastatin. Hepatology 1990;11:764–72., , , .
Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest 1987;80:1692–7., , .
Use of simvastatin plus cholestyramine in the treatment of lysosomal acid lipase deficiency. J Pediatr 1991;119:1008–9., , .
Lovastatin therapy for cholesterol ester storage disease in two sisters. J Pediatr 1991;118:131–5., , .
Enzyme therapy for lysosomal acid lipase deficiency in the mouse. Hum Mol Genet 2001;10:1639–48., , .
Lysosomal acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in mice. Hum Gene Ther 2002;13:1361–72., , .
The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001:3421–51., . The mucopolysaccharidoses. In: , , .
Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182–8., , .
Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004;144:574–80., , .
Hepatic fibrosis in the mucopolysaccharidoses. Am J Med 1986;81:825–9., .
Pathology of the liver in mucopolysaccharidosis: light and electron microscopic assessment before and after bone marrow transplantation. Bone Marrow Transplant 1992;10:273–80., , .
Light and electron microscopic features of the liver in mucopolysaccharidosis. Hum Pathol 1994;25:276–86., , .
The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr 2004;144:S27–34..
Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J Inherit Metab Dis 1999;22:50–62., , .
Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996;87:4894–902., , .
Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood 1998;91:2601–8., , .
Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling. J Inherit Metab Dis 1999;22:849–50., .
Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant 1998;21:629–34., , .
Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase). J Pediatr 2004;144:581–8., , .
The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001;3469–82., . I-cell disease and pseudo-Hurler polydystrophy: disorders of lysosomal enzyme phosphorylation and localization. In: , , .
Molecular basis of variant pseudo-Hurler polydystrophy (mucolipidosis IIIC). J Clin Invest 2000;105:673–81., , .
Mucolipidosis II and mucolipidosis IIIA are caused by mutations in the GlcNAc-phosphotransferace a/B gene on chromosome 12. Am J Hum Genet 1998;63:A15., , .
Missense mutations in N-acetylglucosamine-1-phosphotransferase α/β subunit gene in a patient with mucolipidosis III and a mild clinical phenotype. Am J Med Genet A 2005;137:235–40., , .
Mucolipidosis II (I-cell disease) presenting as neonatal cholestasis. J Inherit Metab Dis 2001;24:603–4., , , .
I-cell disease: a clinical picture. J Pediatr 1971;79:360–5., , .
Neonatal presentation of I-cell disease. J Pediatr 1978;93:954–8., , .
Investigation of lysosomal storage diseases in nonimmune hydrops fetalis. Prenat Diagn 2004;24:653–7., , .
Clinical variability in mucolipidosis III (pseudo-Hurler polydystrophy). Am J Med Genet 2002;108:214–18., , , .
Mucolipidosis III (pseudo-Hurler polydystrophy): Clinical and laboratory studies in a series of 12 patients. Johns Hopkins Med J 1975;137:156–75., , .
Hepatic ultrastructure and histochemistry in mucolipidosis II (I-cell disease). Pediatr Res 1973;7:560–8., , .
Continued neurocognitive development and prevention of cardiopulmonary complications after successful BMT for I-cell disease: a long-term follow-up report. Bone Marrow Transplant 2003;32:957–60., , .
The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001:3725–32., . Multiple sulfatase deficiency and the nature of the sulfatase family. In: , , .
Unusual clinical presentation in two cases of multiple sulfatase deficiency. Pediatr Dermatol 2001;18:388–92., , .
Multiple sulphatase deficiency presenting at birth. Clin Genet 1986;30:409–15., , .
Early manifestations of multiple sulfatase deficiency. J Pediatr 1984;104:574–8., , .
Clinical and mutational characterization of three patients with multiple sulfatase deficiency: report of a new splicing mutation. Mol Genet Metab 2005;86:206–11., , .
Pathologic findings of multiple sulfatase deficiency reflect the pattern of enzyme deficiencies. Pediatr Neurol 1998;19:372–6., , .
Multiple sulphatase deficiency with early onset. J Inherit Metab Dis 1981;4:103–4., , .
Sulfatases and human disease. Annu Rev Genomics Hum Genet 2005;6:355–79., .
Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(α)-formylglycine generating enzyme. Cell 2003;113:435–44., , .
The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell 2003;113:445–56., , .
A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency. Cell 1995;82:271–8., , , .
Sequence determinants directing conversion of cysteine to formylglycine in eukaryotic sulfatases. EMBO J 1999;18:2084–91., , .
A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465–73., , .